These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6753860)

  • 21. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M; de Maat MP; Knipscheer HC; Kastelein JJ; Kluft C; Princen HM; Kooistra T
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
    Raslová K; Nagyová A; Dobiásová M; Ptácková K; Dusinská M
    Acta Diabetol; 2000; 37(3):131-4. PubMed ID: 11277313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
    Paragh G; Seres I; Harangi M; Erdei A; Audikovszky M; Debreczeni L; Kovácsay A; Illyés L; Pados G
    Br J Clin Pharmacol; 2006 Jun; 61(6):694-701. PubMed ID: 16722831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM; Branco MC; Pereira M; Figueiredo H; Jesus LC; de Moura JP; Ferreira MR; Serra e Silva P
    Rev Port Cardiol; 1995 Apr; 14(4):313-22, 284. PubMed ID: 7612280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
    Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AF; Imholz BP; Durrington PN; Trip MD; Eriksson M; Visseren FL; Schaefer JR; Kastelein JJ;
    Clin Ther; 2010 Apr; 32(4):615-25. PubMed ID: 20435231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.
    Desager JP; Horsmans Y; Vandenplas C; Harvengt C
    Atherosclerosis; 1996 Jul; 124 Suppl():S65-73. PubMed ID: 8831918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.
    Stewart JM; Packard CJ; Lorimer AR; Boag DE; Shepherd J
    Atherosclerosis; 1982 Sep; 44(3):355-65. PubMed ID: 6293516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
    Wirth A; Middelhoff G; Braeuning C; Schlierf G
    Atherosclerosis; 1982 Dec; 45(3):291-7. PubMed ID: 7159500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
    Simpson IA; Lorimer AR; Walker ID; Davidson JF
    Thromb Haemost; 1985 Aug; 54(2):442-4. PubMed ID: 4082082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.